Evidence map›Paper›PMID 22336108›Full record

ArticleBMC cancer2012

Regulation of p14ARF expression by miR-24: a potential mechanism compromising the p53 response during retinoblastoma development.

Kwong-Him To, Sanja Pajovic, Brenda L Gallie, Brigitte L Thériault

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Biomarkers in retinoblastoma.International journal of ophthalmology · 2020
    Review
  10. Expression profiles and prognostic value of miRNAs in retinoblastoma.Journal of cancer research and clinical oncology · 2019
    Review
  11. Non-Coding RNAs in Retinoblastoma.Frontiers in genetics · 2019
    Review
  12. Article
  13. Article
  14. Article
  15. Epigenetic regulation of human retinoblastoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Kwong-Him ToCampbell Family Institute for Cancer Research, Ontario Cancer Institute, University Health Network, Toronto, ON, Canada.
Sanja Pajovic
Brenda L Gallie
Brigitte L Thériault
Ontario Institute for Cancer Research · CAHospital for Sick Children · CAToronto Western Hospital · CA

Funding

Progression from Developing Retina to RetinoblastomaR01CA118830 · NCI · UNIVERSITY HEALTH NETWORK · PI GALLIE, BRENDA L · 2005 to 2009
$1.0M
NCI NIH HHS 5R01CA118830-04
6 · The paper itself

Abstract

backgroundMost human cancers show inactivation of both pRB- and p53-pathways. While retinoblastomas are initiated by loss of the RB1 tumor suppressor gene, TP53 mutations have not been found. High expression of the p53-antagonist MDM2 in human retinoblastomas may compromise p53 tumor surveillance so that TP53 mutations are not selected for in retinoblastoma tumorigenesis. We previously showed that p14ARF protein, which activates p53 by inhibiting MDM2, is low in retinoblastomas despite high mRNA expression.

methodsIn human fetal retinas, adult retinas, and retinoblastoma cells, we determined endogenous p14ARF mRNA, ARF protein, and miR-24 expression, while integrity of p53 signalling in WERI-Rb1 cells was tested using an adenovirus vector expressing p14ARF. To study p14ARF biogenesis, retinoblastoma cells were treated with the proteasome inhibitor, MG132, and siRNA against miR-24.

resultsIn human retinoblastoma cell lines, p14ARF mRNA was disproportionally high relative to the level of p14ARF protein expression, suggesting a perturbation of p14ARF regulation. When p14ARF was over-expressed by an adenovirus vector, expression of p53 and downstream targets increased and cell growth was inhibited indicating an intact p14ARF-p53 axis. To investigate the discrepancy between p14ARF mRNA and protein in retinoblastoma, we examined p14ARF biogenesis. The proteasome inhibitor, MG132, did not cause p14ARF accumulation, although p14ARF normally is degraded by proteasomes. miR-24, a microRNA that represses p14ARF expression, is expressed in retinoblastoma cell lines and correlates with lower protein expression when compared to other cell lines with high p14ARF mRNA. Transient over-expression of siRNA against miR-24 led to elevated p14ARF protein in retinoblastoma cells.

conclusionsIn retinoblastoma cells where high levels of p14ARF mRNA are not accompanied by high p14ARF protein, we found a correlation between miR-24 expression and low p14ARF protein. p14ARF protein levels were restored without change in mRNA abundance upon miR-24 inhibition suggesting that miR-24 could functionally repress expression, effectively blocking p53 tumor surveillance. During retinal tumorigenesis, miR-24 may intrinsically compromise the p53 response to RB1 loss.

Indexed as

Gene Expression Regulation, NeoplasticCell Line, TumorCysteine Proteinase InhibitorsHumansLeupeptinsMicroRNAsRetinaRetinal NeoplasmsRetinoblastomaRNARNA, MitochondrialRNA, Small InterferingTumor Suppressor Protein p14ARFTumor Suppressor Protein p53benzyloxycarbonylleucyl-leucyl-leucine aldehydeCysteine Proteinase InhibitorsLeupeptinsMicroRNAsMIRN24 microRNA, humanRNARNA, MitochondrialRNA, Small InterferingTumor Suppressor Protein p14ARFTumor Suppressor Protein p53

Identifiers

PMID22336108
PMCPMC3305684
OpenAlexW1968424416

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.